These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23903569)

  • 21. Orphan drug product regulation--United States.
    Haffner ME
    Int J Clin Pharmacol Ther; 2002 Feb; 40(2):84-8. PubMed ID: 11862977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of orphan products by the U.S. Food and Drug Administration.
    Haffner ME; Kelsey JV
    Int J Technol Assess Health Care; 1992; 8(4):647-57. PubMed ID: 1464485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME
    N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
    [No Abstract]   [Full Text] [Related]  

  • 24. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.
    Henry V
    J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452
    [No Abstract]   [Full Text] [Related]  

  • 25. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
    Tambuyzer E
    Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 27. Health care policy. Reforming off-label promotion to enhance orphan disease treatment.
    Liang BA; Mackey T
    Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234
    [No Abstract]   [Full Text] [Related]  

  • 28. Protein replacement therapies for rare diseases: a breeze for regulatory approval?
    Gorzelany JA; de Souza MP
    Sci Transl Med; 2013 Mar; 5(178):178fs10. PubMed ID: 23536010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 30. Expansion of the Priority Review Voucher Program Under the 21
    Sinha MS; Jain N; Hwang T; Kesselheim AS
    Am J Law Med; 2018 May; 44(2-3):329-341. PubMed ID: 30106661
    [No Abstract]   [Full Text] [Related]  

  • 31. Orphan drug regulations. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2013 Jun; 78(113):35117-35. PubMed ID: 23767079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do investors value the FDA orphan drug designation?
    Miller KL
    Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
    Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.
    Kesselheim AS; Treasure CL; Joffe S
    PLoS Med; 2017 Jan; 14(1):e1002190. PubMed ID: 28045970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Precision Medicines' Impact on Orphan Drug Designation.
    Mueller CM; Rao GR; Miller Needleman KI
    Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution and current status of the Orphan Drug Act.
    Asbury CH
    Int J Technol Assess Health Care; 1992; 8(4):573-82. PubMed ID: 1464479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status.
    Cohen MH; Moses ML; Pazdur R
    Oncologist; 2002; 7(5):390-2. PubMed ID: 12401900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abuses of FDA Regulatory Procedures - The Case of Suboxone.
    Haffajee RL; Frank RG
    N Engl J Med; 2020 Feb; 382(6):496-498. PubMed ID: 31914238
    [No Abstract]   [Full Text] [Related]  

  • 39. Incentives for drug development--the curious case of colchicine.
    Kesselheim AS; Solomon DH
    N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.